Author: bpc

Stephen Saad’s address on the occasion of President Cyril Ramaphosa’s visit at our Sterile Facility in the Eastern Cape at which time he announced the agreement reached with Johnson & Johnson to supply 250 million covid-19 vaccines to Africa, with 30 million being for South Africa

Gqeberha, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today hosted President Cyril Ramaphosa and an accompanying government delegation at its flagship manufacturing site in the Eastern Cape. Aspen has invested in excess of R3.0 billion at this sterile manufacturing site, the single largest investment in the pharmaceutical industry in South Africa. The new… Continue reading Aspen welcomes President Ramaphosa and his delegation to Aspen’s world class sterile manufacturing facility

“Our Aspen philosophy has always been to give purpose to life. This is best achieved by contributing meaningfully to others. Aspen has defined itself and continues to define itself as a company that serves humanity, particularly the most vulnerable amongst us. It was over a decade ago that we made a special announcement on a… Continue reading Stephen Saad, Aspen Chief Executive address to President Ramaphosa and his delegation at Aspen’s flagship manufacturing site in Gqberha, Eastern Cape

Durban, South Africa – Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial… Continue reading Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate